Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Archive for March, 2014

14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London

Posted in Conference Coverage with Social Media, Pharmaceutical Analytics, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Pharmacogenomics, Population Health Management, Genetics & Pharmaceutical, Population Health Management, Nutrition and Phytochemistry on March 25, 2014| Leave a Comment »

14th ANNUAL
BIOTECH IN EUROPE FORUM
For Global Partnering & Investment

30th September – 1st October 2014 • Congress Center Basel

SACHS Associates, London

Conference website

http://www.sachsforum.com/basel14/index.html

 #Sachs14thBEF

Conference AGENDA

http://www.sachsforum.com/basel14/basel14-agenda.html

UPDATED on 8/4/2014 – SEE BELOW

http://www.sachsforum.com/basel14/Basel14-agenda.pdf

Sachs Associates is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

 

Financial/Advisory Investors attending the 2014 Forum include:

AbbVie Biotech Ventures, Inc. Advent Life Sciences Aescap Venture Management BV Aglaia Biomedical Ventures B.V. Amgen Ventures AmorChem apo Asset Management GmbH Aravis AG Aurum Ventures MKI Ltd. Bay City Capital BB Biotech Ventures Bergmann zur Hausen & Cie. GmbH BioMedPartners AG Boehringer Ingelheim Venture Fund Breslin AG Capricorn Venture Partners CD-Venture GmbH Cederberg GmbH CFP BioConnect AG Citi Group Creathor Ventures Cukierman & Co. Life Sciences Deutsche Bank AG Edison Investment Research Edmond de Rothschild Investment Partners Ernst & Young European Investment Fund Excellentia Gloabl Partners F. Hoffmann-La Roche AG Roche Venture Fund Forbion Capital Partners Fraser Finance Global Life Science Ventures HBM Partners AG HealthCap High-Tech Gruenderfonds Management GmbH IBB: Venture Capital Berlin Imperial Innovations Industrifonden JSB Partners LP Knoll Capital Management Kreos Capital Life Sciences Partners Lundbeckford Ventures LSP Medical Strategy GmbH MedVenture Partners GmbH MRL Ventures, Merck & Co., Inc. MS Ventures Nextech Invest Ltd NGN Captial Novartis Venture Fund Novo A/S NRW Bank Omega Funds Oriel Securities Limited Osprey Capital Partners Inc. Percipient Capital Pfizer Venture Investments Piper Jaffray Privateq Advisors AG Remaco AG RMI Partners Rosetta Capital Limited S.R.One, Limited SBS Investments Seroba Kernel Life Sciences Ltd. Siemens Technology Accelerator GmbH Silicon Valley Bank Sofinnova Partners Spinnovator – Ascenion GmbH Takeda Ventures, Inc. TEL Venture Capital, Inc Teralys Capital The Welcome Trust Torreya Partners (Europe) LLC TVM Capital Ventac Partners Vesalius Biocapital VI Partners Vinci Capital Visium Asset UK LLP Warwick Ventures Ltd Wellington Partners XOventure GmbH Yorkville Advisors, LLC Ysios Capital Partners

Announcement

LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE

will cover the event for the Scientific Media

Dr. Lev-Ari will be in attendance on 9/30 and 10/1/2014 at 

Congress Center Basel, Switzerland

by

SACHS Associates, London

http://www.sachsforum.com/basel14/Basel14-agenda.pdf

 

14th ANNUAL
BIOTECH IN EUROPE FORUM
For Global Partnering & Investment

30th September – 1st October 2014 • Congress Center Basel

SACHS Associates, London

http://www.sachsforum.com/basel14/basel14-agenda.html

With an exciting new location, Basel, and expanded programme, we would like to invite you to join The 14th Annual Biotech in Europe Forum for Global Partnering & Investment. The Forum is recognised as the leading international stage for those interested in investing & partnering with the biotech and life science industry in Europe. There are numerous networking opportunities including a reception in the city on the evening of 30th, online 1-2-1 meeting system with meeting facilities and exhibition.

WE WOULD ALSO LIKE TO HIGHLIGHT:

• New Panels Added for 2014

– Drug Development and Manufacturing

– Pricing and Reimbursement.

Forum Agenda Now Online – click here to view

• Financial, Advisory and Investors Attending include:

AbbVie Biotech Ventures, Inc. • Advent Life Sciences • Aescap Venture Management BV • Aglaia Biomedical Ventures B.V. • Amgen Ventures

To view full list – click HERE  

• Attendees:

AbbVie • Abingworth LLP • Actelion Pharmaceuticals, Ltd • ActoGeniX NV • Advent Life Sciences

To view full list – click HERE  

• Confirmed Presenting Companies:

Actogenix NV • AFreeze GmbH • AIDD • Akron Molecules AG • AM-Pharma • AnaptysBio, Inc. • Anergis SA • APEIRON Biologics AG • APEPTICO • Arisgen SA • Asceneuron SA • B-Cell Design • BioCrea • BiolineRx • Biomay • Canbex Therapeutics Ltd. • CAP-CMV GmbH • Dana Farber Cancer Institute • Epigenomics AG • F-star Biotechnology Ltd. • Heptares Therapeutics Limited • Idera • InnoMedica Holding AG • Isarna Therapeutics • Karus Therapeutics • Lanthio Pharma • Lorus Therapeutics • MaxCyte, Inc. • Minoryx Therapeutics s.l. • Mucosis B.V. • Mymetics S.A. • NBE-Therapeutics • Neovacs • Novogen Ltd • Numab AG • Oncos Therapeutics • Opexa • Oryzon • OticPharma Ltd. • PCI Biotech • Pharmaco-Kinesis Corporation • Piqur Therapeutics AG • Re-pharm • Russian Pharmaceutical Technologies • Scancell Limited • Scil Proteins • Spectrum Pharmaceuticals • Synthena AG • Synthon Biopharma • Ugichem • VBI Vaccines • and more TBA. 

FORUM PANELS WILL INCLUDE:

• Public Markets and M&A
• Future of Specialty Pharma
• Investment
• Partnering
• Early Stage Investment
• Scientific Collaborations
• Pricing and Reimbursement
• Drug Development and Manufacturing
• Israel
• Specific Therapeutic Panels:

– Autoimmune & Inflammatory

– CV & Metabolic Diseases

– Infectious Diseases

– Microbiome & Nutrition

– Neuroscience – Oncology

– Personalised Medicine & Diagnostics

– Platform Technologies & Novel Therapeutics

– Vaccines

Opportunities are available for you to join the event either as a delegate, presenter or exhibitor.

Please note we have limited presenting and exhibiting opportunities available.

♦ To enquire about Attending as a delegate click HERE.

♦ To enquire about Presenting click HERE.

♦ To enquire about Exhibiting click HERE.

We have reserved a number of complimentary places for accredited investors.

♦ To enquire about an accredited investor complimentary place click HERE

_______________________________

Please find information about special negotiated rates for events attendees at the local hotels at: https://hotel.basel.com/bpf2014/E 

Confirmed Speakers & Chairs include:

Keynote Speakers:

• Anthony Rosenberg, Head of Global M&A and Licensing, Novartis Pharma AG
• Iris Welten, CEO, Basel Area
• Reinhard J. Ambros, Global Head, Novartis Venture Fund

Speakers:

• Alain Huriez, Venture Partner, Advent Life Sciences
• Andre Hoekema, Senior Vice President Corporate Development, Galapagos
• Andrew Macpherson, Professor Immunology, University of Bern
• Avi Spier, Director, Strategic Alliances, Novartis Institute for BioMedical Research, Inc.
• Barbara Dalton, VP Venture Capital, Pfizer Inc.
• Bernard Coulie, CEO, ActoGeniX NV
• Bernard Sixt, CEO, ImmunID
• Bernd Goergen, Investment Director, High-Tech Gruenderfonds Management GmbH
• Björn Odlander, Founding Partner, HealthCap
• Carlos Buesa, CEO, ORYZON
• Carole Nuechterlein, Head of Roche Venture Fund Basel, Roche Venture Fund
• Chris Britten, Head, Business Development, Sanofi Pasteur MSD
• Chris Maggos, Business Development, Alpine Institute for Drug Discovery
• Christina Takke, Partner, Forbion Capital Partners
• Christoph Pittius, VP, Head of Transactions, Business Development, Global Product and Portfolio Strategy, AstraZeneca
• Corrine Savill, Head Business Development & Licensing, Novartis Pharma AG
• Daniel Dornbusch, Chief Commercial Officer, Nodality, Inc.
• Dan J. Gelvin, Managing Director, Life Sciences, Aurum Ventures MKI Ltd.
• David Alderson, EU Practice Lead, Global Market Access Consulting, Evidera
• David Colpman, Head of Global Business Development, Shire
• Deborah Harland, General Partner, SR One
• Dirk Beher, CEO, ASCENEURON SA
• Prof. Edwin Constable, Head of Research, University of Basel
• Erik van den Berg, CEO, AM-Pharma B.V.
• Esteban Pombo-Villar, Chief Operating Officer, Oxford BioTherapeutics AG
• Dr Fintan Walton, Founder and CEO, PharmaVentures
• Florian Schödel, Owner, Philimmune, LLC
• Dr Frank Grams, VP, Head R&D Alliance Management & Contracting, Sanofi
• Frank Kalkbrenner, Vice President, Head of the Boehringer Ingelheim Venture Fund, Boehringer Ingelheim GmbH
• Genghis Lloyd-Harris, Partner, Abingworth LLP

To view the full list of speakers please click HERE  

Presenting Opportunities

Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business.

Sponsorship and Exhibition

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Raise your company’s profile directly with your potential clients. All of our sponsorship packages and exhibition packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please click the links at the top of the email or contact Mina Orda + 44 (0)203 463 4890

or by email: Mina Orda.

Warm Regards The Sachs Associates Team 27 Belsize Lane, London NW3 5AS Tel: +44 (0)203 463 4890 • Fax: +44 (0)207 691 7919 • www.SachsForum.com

To UNSUBSCRIBE click HERE

Follow us on Twitter @SachsAssociates   Sponsored and supported by:

SOURCE

From: Ann Harris <ann@sachsforum.com>
Reply-To: <ann@sachsforum.com>
Date: Tue, 17 Jun 2014 15:08:59 +0100
To: <avivalev-ari@alum.berkeley.edu>
Subject: Agenda Now Online for the 14th Annual Biotech in Europe Investor Forum

About the 14th Annual Biotech in Europe Forum

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies.

The 14th Annual is held for the first time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one- to- one meetings as well as significant exhibition space. The Programme will feature twelve plenary panels/workshops covering BD & Licensing in the main therapeutic areas. There will be significant networking opportunities at the Forum and receptions.

Forum Panels will include:

• Public Markets and M&A
• Investment
• Partnering
• Early Stage Investment
• Regional Clusters
• Future of Specialty Pharma in Europe
• Israel
• Scientific Collaborations
• Pricing and Reimbursement
• Drug Discovery and Development
• Specific Therapeutic Panels:
  • Autoimmune & Inflammatory
  • CV & Metabolic Diseases
  • Microbiome & Nutrition
  • Infectious Diseases
  • Neuroscience
  • Oncology
  • Personalised Medicine & Diagnostics
  • Platform Technologies & Novel Therapeutics
  • Vaccines

---

Confirmed Speakers include:

Keynote Speakers:

• Anthony Rosenberg, Head of Global M&A and Licensing, Novartis Pharma AG
• Iris Welten, CEO, Basel Area
• Reinhard J. Ambros, Global Head, Novartis Venture Fund

Speakers:

• Alain Huriez, Venture Partner, Advent Life Sciences
• Andre Hoekema, Senior Vice President Corporate Development, Galapagos
• Andrew Macpherson, Professor Immunology, University of Bern
• Avi Spier, Director, Strategic Alliances, Novartis Institute for BioMedical Research, Inc.
• Barbara Dalton, VP Venture Capital, Pfizer Inc.
• Bernard Coulie, CEO, ActoGeniX NV
• Bernard Sixt, CEO, ImmunID
• Bernd Goergen, Investment Director, High-Tech Gruenderfonds Management GmbH
• Björn Odlander, Founding Partner, HealthCap
• Carlos Buesa, CEO, ORYZON
• Carole Nuechterlein, Head of Roche Venture Fund Basel, Roche Venture Fund
• Chris Britten, Head, Business Development, Sanofi Pasteur MSD
• Chris Maggos, Business Development, Alpine Institute for Drug Discovery
• Christina Takke, Partner, Forbion Capital Partners
• Christoph Pittius, VP, Head of Transactions, Business Development, Global Product and Portfolio Strategy, AstraZeneca
• Corrine Savill, Head Business Development & Licensing, Novartis Pharma AG
• Daniel Dornbusch, Chief Commercial Officer, Nodality, Inc.
• David Colpman, Head of Global Business Development, Shire
• Deborah Harland, General Partner, SR One
• Dirk Beher, CEO, ASCENEURON SA
• Prof. Edwin Constable, Head of Research, University of Basel
• Erik van den Berg, CEO, AM-Pharma B.V.
• Esteban Pombo-Villar, Chief Operating Officer, Oxford BioTherapeutics AG
• Dr Fintan Walton, Founder and CEO, PharmaVentures
• Dr Frank Grams, VP, Head R&D Alliance Management & Contracting, Sanofi
• Frank Kalkbrenner, Vice President, Head of the Boehringer Ingelheim Venture Fund,
  Boehringer Ingelheim GmbH
• Genghis Lloyd-Harris, Partner, Abingworth LLP
• Graeme Martin, President and CEO, Takeda Research Investment
• Graham Kelly, Chief Executive Officer, Novogen Ltd
• Graziano Seghezzi, Partner, Sofinnova Partners
• Guillaume Vignon, Director Business Development Oncology – Global Business Development and Licensing, EMD Serono
• Hakan Goker, Investment Director, MS Ventures
• Hamza Suria, President & CEO, AnaptysBio, Inc.
• Jane Dancer, Chief Business Officer, F-star Biotechnology Ltd.
• Janet Hammond, Vice President, Translational Medicine – Virology in Pharmaceutical Research and Early Development (pRED), F.Hoffmann La Roche AG
• Janis Naeve, Managing Director, Amgen Ventures
• Jason Coloma, Global Head Venture & Innovation at Roche Partnering,
  F.Hoffmann La Roche AG
• Jeff Baxter, CEO, VBI Vaccines
• Jesse Schulman, CEO, Canbex Therapeutics Ltd.
• Johan Verbeeck, Senior Director of Partnership Management, Johnson & Johnson Innovation Center, Janssen Pharmaceutical Companies of Johnson & Johnson
• Johannes F. Zanzinger, Global Head, CardioMetabolic Business Development and Licensing,Boehringer Ingelheim Pharma GmbH & Co. KG
• John Gustofson, Senior Director, Venture and Early Stage Colaboration, AbbVie
• Kai Brüning, Senior Portfolio Manager, apo Asset Management GmbH
• Katya Smirnyagina, Partner, Capricorn Venture Partners
• Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
• Laurenz Kellenberger, CSO, Basilea
• Lorenza Castellon, Business Development Consultant, Suda Ltd.
• Lothar Steidler, Vice President Technology, ActoGeniX
• Lubor Gaal, Head of Europe, Strategic Transactions Group, BMS
• Luca Bolliger, VP and Group Licensing Director, RECORDATI S.A.
• Madhusudan V. Peshwa, Executive Vice President, Cellular Therapeutics, MaxCyte, Inc.
• Maina Bhaman, Director, Healthcare Ventures, Imperial Innovations
• Malcolm Weir, Co-Founder and Chief Executive Officer, Heptares Therapeutics
• Markus Ewert, EVP Business Development, GE Healthcare
• Matthieu Coutet, Managing Partner, Inserm Transfert Initiative
• Michael J. Hanewich, Managing Director, Healthcare and Life Science Venture Capital,
  Silicon Valley Bank
• Michael Shalmi, Senior Partner, Novo A/S
• N. Roa Movva, Novartis Distinguished Scientist, Executive Director,
  DMP/NIBR/Novartis Pharma AG
• Nicholas Franco, Executive Vice President & Chief Business Development Officer,
  Actelion Pharmaceuticals, Ltd
• O. Prem Das, Chief Research Business Development Officer and Heads DFCI’s Office of Research and Technology Ventures (ORTV), Dana-Farber Cancer Institute (DFCI)
• Oliver Middendorp, Co-CEO & CBO, Numab AG
• Peter Burckhardt, Chief Executive Officer, EVA – the Basel life sciences start-up agency
• Philip A. Serlin, Chief Financial and Operating Officer, BioLineRx, Ltd.
• Philippe Calais, CEO, Isarna Therapeutics GmbH
• Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Licensing & Business Development, MERCK KGaA / EMD
• Pierre Vandepapeliere, CMO, Neovacs
• Rainer Henning, CEO, Biomay AG
• Rainer Metzger, VP Global Business Development Pharma, QIAGEN GmbH
• Rainer Strohmenger, General Partner, Wellington Partners
• Reid J. Leonard, Managing Director, MRL Ventures, Merck & Co., Inc.
• Richard Goodfellow, CEO, Scancell Holdings plc
• Robin Davison, Director, Healthcare, Edison Investment Research
• Søren Møller, Managing Investment Director, Novo Seeds
• Stefan Frings, Global Head, Oncology Immunology Therapeutic Area, Roche
• Stephanie Léouzon, Principal and Head of Torreya Partners Europe, Torreya Partners
• Stewart Kay, Director Transactions, Worldwide Business Development, GSK
• Susan Hill, Director of Global Business Development, Alexion Pharma International Sarl
• Thomas Stockman, Director, Healthcare Investment Banking, Citi Group
• Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
• Tim Knotnerus, Director Business Development, Am-Pharma
• Tom Johnston, CEO, Mucosis B.V.
• Tom Kronbach, CEO, BioCrea
• Tomas Landh, Director, Strategy and Innovation Sourcing, Novo Nordisk
• Ulf Grawunder, CEO, NBE-Therapeutics Ltd
• Vincent Charlon, CEO, Anergis SA
• Vladimir Cmiljanovic, CEO, PIQUR Therapeutics AG
• Wilder Fulford, Principal, Torreya Partners (Europe) LLC
• And More TBA…

---

Presenting Opportunities

Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business.

Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures as well as access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and provide once again, opportunities for executive-level networking, deal-making and strategic partnering.

The forum is recognised as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners.

Sponsorship

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please contact
Mina Orda + 44 (0)203 463 4890 or by email: Mina Orda.

 

SOURCE

http://www.sachsforum.com/basel14/index.html

Editorials of event coverage via our Open Access Scientific Journal

http://pharmaceuticalintelligence.com

Scientific Journal Site Statistics

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

07/29/2013   217,356 1,138 1,389 705
12/01/2013   287,645 1,428 1,676 828
02/09/2014   325,039 1,665 1,793 892
03/05/2014   338,958 1,717 1,830 965
03/21/2014   347,667 1,750 1,838 974

03/31/2014  352,683 1,768 1,869 991

05/12/2014  373.696  1,878  1,944  1,035

06/18/2014  393,111  1,992  1,982  1,087

7/27/2014  418,570  2,098  2.050  1,124

9/2/2014  444,222  2,226  2,104  1,170

09/02/2014  

444.222 Views  

2,226 Articles  

NATURE clicks 1,170

ncbi.nlm.nih.gov clicks  2,104

fda.gov  clicks 198

cancer.gov  clicks  162

 

Pre e-Pub e-Books Flyers

• Genomics Orientations for Individualized Medicine

• Cancer Biology and Genomics for Disease Diagnosis

 

Series C: e-Books on Cancer & Oncology

Volume One: Cancer Biology and Genomics for Disease Diagnosis

http://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/cancer-biology-and-genomics-for-disease-diagnosis/

Volume Two: Therapies in Cancer – Surgery, Radiation, Chemo and Immunotherapies

http://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/volume-2-immunotherapy-in-oncology/

Series B: Frontiers in Genomics Research

Volume One: Genomics Orientations for Individualized Medicine

http://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

GENOMICS related articles in the JOURNAL

• Cardiovascular Pharmacogenomics – 134 articles
• Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics – 55 articles
• Nutrigenomics – 43 articles
• Pharmacogenomics – 88 articles
• Genomic Testing: Methodology for Diagnosis – 241 articles
• Personalized Medicine & Genomic Research – 390 articles
• Genome Biology – 421 articles

Genomics Orientations for Individualized Medicine

Volume One

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading...

Read Full Post »

REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via Twitter.com @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Interviews with Scientific Leaders, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Technology Transfer: Biotech and Pharmaceutical, Translational Science on March 21, 2014| Leave a Comment »

REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via Twitter.com @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

Author, Curator, Life Sciences Reporter: Aviva Lev-Ari, PhD, RN

Article ID #123: REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via Twitter.com @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA. Published on 3/21/2014

WordCloud Image Produced by Adam Tubman

This article is by the same Curator as the following published on 1/4/2014:

conceived: NEW Definition for Co-Curation in Medical Research

RELATED ARTICLES

Cancer Biology and Genomics for Disease Diagnosis, Volume One Pre-ePub Announcement

Volatile Organic Compounds (VOCs) as Biomarkers in Cancer Detection: • Alnion Ranked #1 in “Top 10 Israeli medical advances to watch in 2014”.

Investing and inventing: Is the Tango of Mars and Venus Still on

Curator’s Position Statement

The complexity of presentations in Scientific Conferences requires a different Reporting methodology than the idea summarization by Science Journalists.

A Novel Methodology was applied @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Collaboration & Investment in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

Launched a novel methodology for Authentic Reporting on Presentations and Discussions in my quest to achieve REAL TIME Cancer Conference Coverage of content and Q&A.

Of all Social Media modalities I used the following:

• Primary: Tweeting key idea by EVERY SPEAKER
• Secondary: Tweeting all Q&A and Discussions
• FaceBook posting
• LinkedIn posting
• WordPress.com e-Publishing @ http://pharmaceuticalinteligence.com

Below I present ALL the Tweets and the Retweets for 3/19/2014

Public and Private Partnership @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Collaboration & Investment in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

March 19, 2014 by 2012pharmaceutical

March 19, 2014 5PM

Public & Private Partnerships

Co-Chaired by:

• Louis J. DeGennaro, Interim President and CEO, Chief Mission Ocer, The Leukemia and Lymphoma Society
• Beth Jacobs, Managing Partner, Excellentia Global Partners Featuring:
• Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
• Dov Hass, Associate, Morgan, Lewis & Bockius LLP
• Kristina Khodova, Head of Oncology Projects, Biomed Cluster, Skolkovo Foundation
• Louise M. Perkins, Chief Science Ocer, Melanoma Research Alliance
• Peter L. Hoang, Managing Director, Oce of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center
• Steven Young, President & COO, Addario Lung Cancer Medical Institute
• Walter M. Capone, President, Multiple Myeloma Research Foundation

Public & Private Partnership

• Foundation are playing a new role: The enable Cancer Research, links to biopharma, Scientific staff, understanding of the commercial landscape
• Universities: Public & Private

Question #1: Difficulties in working with small biotech companies Non-Profits are disease focus, Biotech have expectation to gain capital funding from the Non-Profits Non-Profit has access to Patients information and disease condition in the pre-approval period, Consortia: addresses access to Resources do not invest or fund pharma companies, they fund diagnostics lab, stem cell companies Foundations  have right to publish data, IP ownership is still unresolved an issue, Dana Farber can’t be encouraged to give away its IP but a Foundation can accelerate the process.

IP Licensing Academic institution as LICENSORS WHILE HAVING having bond obligation, Tax exempt status is exclusive, while the bond owner status is non-exclusive Appetite for Risk – Venture Capital vs Foundation

• Louis J. DeGennaro, Interim President and CEO, Chief Mission Ocer, The Leukemia and Lymphoma Society – provides $60 millions a year for R&D – they do take significant Risk. Size of population of patients is not a factor, serving all is. No detection, No screening, Patients present with full blown disease
• Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance — Risk does not belong to this organization. Foundation funded research on the disparity between Black and White patients.
• Louise M. Perkins, Chief Science Officer, Melanoma Research Alliance – UV cause, funding research for personalized. medicine. Foundation has educated FDA, Sequencing of melanoma larger that sequencing of the Genome
• Steven Young, President & COO, Addario Lung Cancer Medical Institute 70% of Lung Cancer Patients were not Smokers

__________________

8:00 AM –

On the 40th Floor of 7 World Trade Center in NYC @  The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Collaboration & Investment in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

Follow me @pharma_BI and @AVIVA1950

• Event Coverage
• Cancer & Genomic – Volume One in LPBI’s BioMed e-Series C: Cancer
• Alnion Venture Funding Prospecting & Negotiation

Aviva Lev-Ari, PhD, RN Founder and Director Leaders in Pharmaceutical Business Intelligence

Editor-in-Chief http://pharmaceuticalintelligence.com

 TWEET LOG for 3/19/2014

1. @pharma_BI ‏@Pharma_BI  Mar 19

   TODAY follow my Tweets @pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering &… http://fb.me/1dvGXjXQC 

2. @pharma_BI ‏@Pharma_BI  Mar 19

   Checkpoint inhibitors: Portfolio of antigens for a small # Tumors. Adjuvant combinations Risks: immune disease vs Cancer

3. @pharma_BI ‏@Pharma_BI  Mar 19

   Argos Therapeutics: Leader in immunotherapy for Advanced Kidney cancer, vaccine development effort

4. @pharma_BI ‏@Pharma_BI  Mar 19

   Tumor blockade via immunotherapy: active therapy, autologos, T cells depleted by kidney and tumor removal, healthy kidney was protected

5. @pharma_BI ‏@Pharma_BI  Mar 19

   Precursors of breast lesions, target antigen, vaccine for cancer MAY or not evolve into immune event in the future

6. @pharma_BI ‏@Pharma_BI  Mar 19

   Immunotherapy in Cancer: Tolerance of Cancer, central (thymus) breast/ovarian vs peripheral by checkpoint: skin, lungs, kidney vs

7. @pharma_BI ‏@Pharma_BI  Mar 19

   Florian Schodel, Philimmune, immunotherapy in Cancer Development: vaccine for Cancer for secondary prevention breast/ovarian cancer

8. @pharma_BI ‏@Pharma_BI  Mar 19

   All Options on the table when financing, best package requires flexibility. Outcome, Output, Process originality do clinical trial, find what kills

9. @pharma_BI ‏@Pharma_BI  Mar 19

   Partnering in Phase I is dangerous vs Stage IV, companion diagnostics, not enough money in the product to share.

10. @pharma_BI ‏@Pharma_BI  Mar 19

    Future Trends in Oncology: preclinical going IPO, China for clinical trial at different standard of care than US or Europe

11. @pharma_BI ‏@Pharma_BI  Mar 19

    Carole Nuechterlein, Head Roche Venture Fund: Big Pharma offers to biotech knowledge on combination drugs to select for development. Biotech tend to overestimate value of the assets

12. @pharma_BI ‏@Pharma_BI  Mar 19

    Tim Herpin, Head Transactions (UK) BD AstraZeneca: Acquisition is preferred to partnership

13. @pharma_BI ‏@Pharma_BI  Mar 19

    Stuart Barich, Oppenheimer & Co. Holding to assets vs. Partnering – HOLD as long as a biotech can

14. @pharma_BI ‏@Pharma_BI  Mar 19

    Anne Altmeyer, VP Oncology, Novartis: Only 5% of all Cancer drugs move from Phase I to phase II – Oncology drugs 36% of all current cancer drugs are in Phase II

15. @pharma_BI ‏@Pharma_BI  Mar 19

    Commercialization is only one factor in Transforming Patient life’s by drug response in clinical trials – repurposed drugs vs generic

16. @pharma_BI ‏@Pharma_BI  Mar 19

    Regulatory affairs: 30% of applications are approved, most cancer indications requires orphan drug development – niche of patient

17. @pharma_BI ‏@Pharma_BI  Mar 19

    Celgene partners with Foundation Medicine or Diagnostics development, Roche has own Diagnostics – small biotech vs big Pharma

18. @pharma_BI ‏@Pharma_BI  Mar 19

    Guillaume Vignon, Dir BD, EMD Serono: Finding the right patient by selection for obtaining response – key for clinical study success & Translational Team

19. @pharma_BI ‏@Pharma_BI  Mar 19

    Anne Altmeyer, VP Oncology Novartis: Strategies for Small Molecule and Biologicals Drug Development, 1/3 of top 100 drugs and 22% of drug approval are Biologicals this is the future

20. @pharma_BI ‏@Pharma_BI  Mar 19

    Moffitt Total Cancer Care DB Solid Tumor signature – Cancer Vaccine, genotype—>>>>phenotype demographic histology over expression of genes

21. @pharma_BI ‏@Pharma_BI  Mar 19

    M2GEN – Concortium with Community Hospitals: WORLD largest biorepository Moffitt/Merck/Community Hospital, Genomic Marker

22. @pharma_BI ‏@Pharma_BI  Mar 19

    J. Mule, Moffitt Cancer Center: Translational Research for Personalized Medicine: M2GEN collaboration StateMerck/Moffitt 3rd largest in US

23. @pharma_BI ‏@Pharma_BI  Mar 19

    BRAF inhibition: not enough patients for genetic mutation based clinical trial, BiomarkersDiagnostics in collaboration w/academia is optimal

24. @pharma_BI ‏@Pharma_BI  Mar 19

    TODAY follow my Tweets @pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering &… http://fb.me/1jxkUHMlJ 

25. @pharma_BI ‏@Pharma_BI  Mar 19

    N.C. Dracopoli of Janssen R&D: Biomarkers for Diagnosis – Prognosis, Predicative test, pharmacodygnostic test FDA 32 genomics biomarkers approved

     
26. @pharma_BI ‏@Pharma_BI  Mar 19

    Tx w/anti-IL-6 for ALL – Great Prognosis, Novartis and UPenn collaboration most promising big Pharma and Academia case

27. @pharma_BI ‏@Pharma_BI  Mar 19

    Philip Gotwals, Oncology Novartis, Translational Research, collaboration with UPenn – Org clarity challenging

28. @pharma_BI ‏@Pharma_BI  Mar 19

    TODAY follow my Tweets @pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoti…http://lnkd.in/dbHd85U

29. @pharma_BI ‏@Pharma_BI  Mar 19

    TODAY follow my Tweets @pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum… http://wp.me/p2kEDv-5AX 

30. @pharma_BI ‏@Pharma_BI  Mar 19

    Cancer Biology and Genomics for Disease Diagnosis, Volume One Pre-ePub Announcement http://lnkd.in/d83gUrY 

31. @pharma_BI ‏@Pharma_BI  Mar 18

    Power of Analogy: Curation in Music, Music Critique as a Curation and Curation of Medical Research Findings – A Comp…http://lnkd.in/dBbahTf 

32. Aviva Lev-Ari ‏@AVIVA1950  Mar 19

• TODAY follow my Tweets @pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering & Invest… http://wp.me/p2kEDv-5AX  via @Pharma_BI
• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Small molecule peptides Roche, Amgen players RNA

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Providus Therapeutics – preclinical small molecule targeting selective kinase inhibitors, mutations, Solution overcoming compensatory feedback

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  TBI 302 Liver Cancer TBI 304 Stimulated hemoglobin – Cancer thirty causes anemia SAME market as EPO

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Therapure Biopharma: Liver cancer, purify hemoglobine, protein drug carrier for drug payload

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Avastin approved for recurring Gliomas

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Neonc Technologies INTERNASAL Brain delivery using CPAP via cranial nerse, by pass BBB. Malignant Gliomas 12-15 mo survival

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Sapherion Therapeutics since 2002 – Myocet: Anthracycline – doxorubicin in combination with transtuzumab and pactistaxal Phase III trial

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Rexahn Pharmaceuticals phase II – Cancer cell specific nucleotide compound that inhibit DNA Synthesis in animal models,

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Children Oncology Local & Metastatic – 2000 kids in US receive Platinum drugs in US. Payers receptive to pay Platinum drug. STS since 2003

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Adherex Technologies, Inc. RTP, NC seeking Partners for Phase III, Platinum drugs, causes hearing loss in children, Adults neck CA

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Rgenix Inc. 100% reduction in Liver methastasis, from colon cancer, relapse in 2-3 years, require work is collaboration with Rockfeller University

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Rgenix, Inc. drug for tumor suppression by gene Apolipho E* 50% survival data fro Sloan Kettering, 80% tumor growth inhibition

•  

  Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Significant extension of life: Pre clinical research results by Intensity Therapeutics

• Aviva Lev-Ari ‏@AVIVA1950  Mar 19

  Intensity Therapeutics: Drug diffuse to cell increasing fusion, tumor regression vs inhibition of growth: completed systemic response 40 days

 Re-TWEETS

1. @pharma_BI ‏@Pharma_BI Mar 19

Future Trends in Oncology: preclinical gong IPO, China for clinical trial at different standard of care than US or Europe

• Retweet 1: Gil Press
• Favorite 1: Kimberly Ha
• 8:23 AM – 19 Mar 2014 · Details

2. @pharma_BI ‏@Pharma_BI Mar 19

Big Pharma offers to biotech knowledge on combination drugs to select for development. Biotech tend to overestimate value of the assets

• Retweet 1: Gil Press

8:35 AM – 19 Mar 2014 · Details

3. @pharma_BI ‏@Pharma_BI Mar 19

Only 5% of all Cancer drugs move from Phase I to phase II -Oncology drugs 36% of all current cancer drugs are in Phase II

• Favorite – Pamela Headfield

7:51 AM – 19 Mar 2014 · Details

4. @pharma_BI ‏@Pharma_BI Mar 19

Commercial only one factor in Transforming Patient life’s by drug response in clinical trials – repurposed drugs vs generic

• Retweet 1 – Gil Press

5. @pharma_BI ‏@Pharma_BI Mar 19

Celgene partners with Foundation Medicine or Diagnostics development, Roche has own Diagnostics – small biotech vs big Pharma

• Retweet 1 – Gil Press

7:03 AM – 19 Mar 2014 · Details

6. @pharma_BI ‏@Pharma_BI Mar 19

TODAY follow my Tweets @pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering &… http://fb.me/1jxkUHMlJ 

• Retweet 1 – Gil Press

6:16 AM – 19 Mar 2014 · Details

7.  @pharma_BI ‏@Pharma_BI Mar 14

The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Col… http://wp.me/p2kEDv-55i  via @Pharma_BI

Retweeted by @pharma_BI

8. Sachs Associates Ltd ‏@SachsAssociates Dec 10

2nd Annual SachsCancerBioPartnering Forum, 19th March, New York. Info: http://goo.gl/GLD3Dg  Early Bird Registration:http://goo.gl/rX0RpW 

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading...

Read Full Post »

« Newer Posts - Older Posts »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Email Address

  Follow

  Join 2,056 other subscribers

• Recent Posts

  • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
  • 2026 World Economic Forum, 1/19 – 1/23/2026, Davos, Switzerland, LPBI Group’s KOLs interpretation of AI in Health Videos January 24, 2026
  • Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality January 12, 2026
  • Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry January 11, 2026
  • List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
  • Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
  • Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com January 10, 2026
  • The youngest leader in AI in Health: Tanishq Mathew Abraham, Ph.D. (@iScienceLuvr) January 8, 2026
  • 2026 Grok Multimodal Causal Reasoning on Proprietary Cariovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage January 6, 2026
  • Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods January 6, 2026

• Archives

  Archives Select Month January 2026  (10) December 2025  (8) November 2025  (8) October 2025  (12) September 2025  (2) July 2025  (4) June 2025  (8) May 2025  (4) April 2025  (2) March 2025  (1) February 2025  (2) January 2025  (3) December 2024  (1) November 2024  (5) October 2024  (7) September 2024  (7) August 2024  (1) June 2024  (1) May 2024  (2) April 2024  (2) January 2024  (1) November 2023  (1) October 2023  (3) September 2023  (3) August 2023  (2) July 2023  (2) June 2023  (7) May 2023  (4) April 2023  (2) March 2023  (5) February 2023  (2) January 2023  (3) December 2022  (2) October 2022  (6) September 2022  (2) August 2022  (1) July 2022  (3) June 2022  (3) May 2022  (8) April 2022  (10) March 2022  (7) February 2022  (7) January 2022  (3) December 2021  (3) November 2021  (4) October 2021  (11) September 2021  (5) August 2021  (8) July 2021  (21) June 2021  (8) May 2021  (10) April 2021  (8) March 2021  (15) February 2021  (17) January 2021  (20) December 2020  (10) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (239)    3D Plotting Scaffolds  (44)    BioInks  (34)       Biopolymer Blend Open Porous  (18)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (77)       Cell Level  (16)       MicroEngineering Cell-Tissue & Systems  (31)       Tissue Engineering  (37)    Cardiovascular and Vascular Systems  (30)       Artificial Vascular Structures  (9)       Cardiovascular Tissue  (8)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (10)    MEMS  (16)       Bio-MEMS  (12)    Organ-on-a-Chip  (11)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (10) Academic Publishing  (223)    Key Opinion Leaders in eScientific Publishing – Interviews with  (8) Advanced Drug Manufacturing Technology  (96)    Antimalarial Preparation  (8)    Autologous Cell Therapy  (14)    Automated Cell Processing  (13) Allergy and Infectious Diseases  (12) Alzheimer’s Disease  (163)    Etiology  (77)    Medical Device Therapies for Altzheimer’s Disease  (15)    Pharmacotherapy and Cell Activity  (51) Anticancer Resistance  (31) Art Exhibits on the Human Condition  (1) Art Inspires Science  (4) Article Type  (2)    Authored  (1)    Curated  (2)    Scientific report  (1) Artificial Heart  (2) Artificial Intelligence – General  (232)    An executive’s guide to AI  (10)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (115)    Artificial Intelligence Applications in Health Care  (125)       Artificial Intelligence in CANCER  (39)       Artificial Intelligence in Health Care – Tools & Innovations  (74)    Artificial Intelligence in Medicine – Application for Diagnosis  (69)       Artificial intelligence applications for cardiology  (31)          AI-assisted Cardiac MRI  (10)       Artificial Intelligence in Psychiatry  (6)       Deep Learning in Pathology  (18)    Artificial Intelligence in Medicine – Applications in Therapeutics  (64)    ChatGPT, GPT-4  (7)       ChatGPT at LPBI Group  (3)       ChatGPT in Academic Education  (3)    Machine Learning  (71)       Deep Learning  (25)       Natural Language Processing (NLP)  (45)    Machine learning in predicting type 2 diabetes  (5) Auditory and vision  (13) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (24)    Crohn’s disease  (5)    Tolerance-inducing Autoimmune Disease Therapeutics  (6)    Ulcerative Colitis  (3) Autophagosome  (4) Bacterial Resistance  (25) Behavior  (26) Behavioral Genetics  (21) Big Data  (88)    Intelligent Information Systems  (51) Bio Instrumentation in Experimental Life Sciences Research  (368)    Analytical Instruments Industry  (5)    Microfuidics  (8) Bio-Ethics  (15) BioBanking  (36) Biodegradable Drug-eluting Material  (8) Bioengineering & reverse engineering design  (43) BioIT: BioInformatics  (147) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (135)    Advanced Computing Platform  (32)       Blockchain Transactions System  (6)          Platform for Content Monetization embedded Content Promotion  (1)    Pancreatic adenocarcinoma classifier  (4)    Simulation Modeling in NGS  (5) Biological Engineering  (43) Biological Networks  (193) Biological Networks, Gene Regulation and Evolution  (479)    Virology  (10) Biomarkers & Medical Diagnostics  (571)    VOC – Volatile Organic Compounds as BioMarkers  (2) Biomedical Measurement Science  (173) BioSimilars  (112) BioTechnology – Venture Creation  (131)    Foundations for supporting Science and Education  (14)    Philanthropy to Academic Institution  (3) BioTechnology – Venture Creation, Venture Capital  (108)    Seeking Talent  (3) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (82) Brain Basis of Emotion  (5) Business Career Consideration  (1) Ca2+ triggered activation  (61) Calcium  (21) Calcium Signaling  (71) Calmodulin Kinase and Contraction  (36) Cancer – General  (186) Cancer and Current Therapeutics  (411)    interventional oncology  (49)       Breast Cancer – impalpable breast lesions  (20)       Prostate Cancer: Monitoring vs Treatment  (9) CANCER BIOLOGY & Innovations in Cancer Therapy  (1,122)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (84)       Circulating Tumor Cells (CTC)  (27)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (17)             mRNA  (6)          MagSifter chip  (1)       KRAS Mutation  (9)       Li-fraumeni syndrome.  (3)       TP53 – Germline mutations  (8)    cancer metabolism  (28)    Funding Opportunities for Cancer Research  (12)    Genomic Expression  (150)    Glioblastoma  (7)    Hexokinase  (14)    Loss of function gene  (18)    Metabolic Immuno-Oncology  (21)    Metastasis Process  (15)    Methylation  (33)    Microbiome and Responses to Cancer Therapy  (10)    Monoclonal Immunotherapy  (29)    mtDNA  (13)    Oxidative phosphorylation  (56)    Pancreatic cancer  (10)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (16)    Warburg effect  (50) Cancer Informatics  (104) Cancer Prevention: Research & Programs  (131) Cancer Screening  (108) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (30)    Engineering Enhanced Cancer Vaccines  (3) cancer-general  (6) Cardiac and Cardiovascular Surgical Procedures  (328)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (91)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (2)       TAVI vs Open Heart Surgery  (6)       Transcatheter Aortic Valve Replacement via the Transcarotid Access  (3)       Transcaval TAVR Procedure  (3)       Valve-in-Valve Procedure  (5)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (18)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (47)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (16)    Heart-Lung Transplant  (11)    Implantation  (3)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (22)    Mitral Valve: Repair and Replacement  (64)       TMVR – Transcatheter Mitral Valve Repair  (5)    PCI  (108)       Bioresorbable Vascular Scaffold (BVS)  (4)       Invasive FFR for PCI  (2)       Multivessel PCI FFR Guidance  (1)       Robotic-assisted percutaneous coronary intervention  (2)       Stent Retriever in endovascular thrombectomy  (3)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (65)       Abdominal Aorta  (20)       Carotid Artery  (15)       Limb ischemia  (4)       Thoracic Aorta  (16)    Pulmonary Valve Replacement and Repair  (3)    Renal Denervation  (20)    Replacement  (1)    Robotically assisted Cardiothoracic Surgery  (2)    Tricuspid Valve Repair  (7)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (2) Cardiovascular Pharmacogenomics  (171) Cargo  (3) Cell Biology  (323) Cell Biology, Signaling & Cell Circuits  (672)    Apoptosis  (17)    Autophagy-Modulating Proteins  (6)    “Antibody–enzyme conjugates”  (6)    Cell Processing System in Cell Therapy Process Development  (27)    Endoplasmic reticulum  (3)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (3)    Ubiquitin  (11) Cerebrovascular and Neurodegenerative Diseases  (123)    Stroke  (9) Chemical Biology and its relations to Metabolic Disease  (464)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (8) Chemical Genetics  (350) Child and Adolescent Psychiatry  (13) Childhood cancer  (17) Childhood malnutrition  (3) children  (3) Circulating Progenitor Cells  (27)    Bone marrow derived cells  (17)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (238) Clinical Diagnostics  (220)    Mass automation of plasma proteins  (13) Clinical Genomics  (144) Coagulation Therapy and Internal Bleeding  (83) Cognition  (47) Commercialization  (20) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (470)    Computational Histopathology  (3)    Meta-analysis of transcriptome data  (10) Conference Coverage with Social Media  (494)    MassBio  (3) coronavirus  (18) COVID-19  (20) CRISPR/Cas9 & Gene Editing  (192)    CRISPR alternative for editing genes without cutting  (14)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (4)    CRISPR applied to Human Germ Line  (13)       Gene Editing Impact on Longevity  (6) CT  (20) Cytokines  (20) Cytoskeleton  (85) Developmental biology  (107) Diabetes Mellitus  (146)    Artificial Pancreas for Type 2 Diabetes  (4)    Artificial Pancreas for Type1 Diabetes  (8)    Gestational diabetes  (5) Diagnostic Immunology  (61) Diagnostics and Lab Tests  (128)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (9) Digital HealthCare – biotech & internet joint ventures  (47) Disease Biology  (334) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (487) DNA repair  (73)    Apoptosis  (13)    Autophagy  (13)    Cell death pathways  (19)    Proteolysis  (8)    Proteosome  (8) Drug Delivery Platform Technology  (157)    Drug Carrier Design  (21)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (9) Drug Toxicity  (74) Ecosystems & Industrial Concentration in the Medical Device Sector  (172)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (10) Embryology  (24) Empathy  (6) Endocrine Diseases  (60) Enzyme Induction  (46)    ion-transporting enzyme  (2)    K + -ATPase.  (1)    Na +  (2) Epigenetics and Environmental Factors  (35) Ethics and Leadership  (10) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (71) FDA Regulatory Affairs  (358)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (52)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fetal Ultrasound  (2) Fiction and medicine  (5) Frontiers in Cardiology and Cardiovascular Disorders  (929)    Acute Myocardial Infarction  (63)       Cardiogenic Shock  (5)    Anemia in CVD Patients  (6)    Cardio-Oncology  (4)    Cardiomyopathy  (57)    Cardiovascular Research  (187)       Myocardial metabolism, Myocardial ischemia, myocardial perfusion, Myocardial adenine nucleotide metabolism  (64)       Pre-Clinical Animal Model Development  (23)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (20)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (111)       Ablation Procedure vs Drug Therapy  (2)       Arrhythmia Detection with Machine Learning Algorithms  (7)       Cardiotoxic Risks of Immune Checkpoint Inhibitors  (1)       Genomic Analysis of EKG Electrophysiology Genomics  (3)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (7)    Epigenetics and Cardiovascular Risks  (57)    Heart Failure (HF)  (51)       Acute coronary syndrome  (7)       congestive heart failure  (19)       Hypertensive Disorders of Pregnancy  (1)    Medical Devices R&D and Inventions  (212)       Assist Devices: LV  (3)       RV  (1)       Stents & Tools  (90)       Valves & Tools  (67)    Origins of Cardiovascular Disease  (422)       Atherogenic Processes & Pathology  (180)       Congenital Heart Disease  (34)          Genetic Mutations in Congenital Heart Disease  (4)       inflammation independent of lipid levels  (13)       Systemic Inflammatory Diseases as CVD Risk  (12)    Pharmacotherapy of Cardiovascular Disease  (356)       HTN  (176)       HTN in Youth  (8)       Resident-cell-based  (43)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (15)       endovascular thrombectomy  (6)    Vascular Diseases  (21)       mesenteric ischemia  (3) Future Pandemics Inform-graphics  (1) Gastroenterology  (38) Gene Regulation  (232) Gene Regulation and Evolution  (137) Genetics & Innovations in Treatment  (176) Genetics & Pharmaceutical  (203) Genome Biology  (967)    Exosomes  (25)    Gene Therapy & Gene Editing Development  (42)    mRNA Therapeutics  (20)    Mutagenesis  (27)    Single Cell Genomics  (25)    Single-cell sequencing  (20)    Variation in human protein-coding regions  (35) Genomic Endocrinology  (42) Genomic Testing: Methodology for Diagnosis  (416) Genomics Pharmacy  (40) Global Market of Medical Devices Technology  (2) Global Medical Publishers by Country  (3) Global Partnering & Biotech Investment  (47) GLP  (4) Glycobiology: Biopharmaceutical Production  (16) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (28) Health Care System by Country  (58)    AI Models in Healthcare  (12)    Centers for Medicare & Medicaid Services  (8)    Health in Israel  (2)    India  (1)    United States  (27)       Hospital-based Medical Innovations  (10)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (384)    Women Health  (18)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (165)    and Bioethics  (14)    Biotechnology  (12)    Health Law Policy  (13) HealthCare IT  (138) Healthcare Reform  (117)    Accountable Care Organizations  (26)    Affordable Care Act  (29)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (26)    Healthcare costs and reimbursement  (59)    Indigent Nutrition  (14)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (21)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (15)    Uninsured and Underinsured  (20) Hematology  (100)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (27) Human Immune System in Health and in Disease  (246) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (21) Image Processing/Computing  (41) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (133)    mRNA platform in Drug DIscovery  (6) Immunodiagnostics  (139)    Cancer-Immune Interactions  (29)    CNS-Immune Interface  (5)    Neuronal Circuits  (4) Immunology  (123)    Adaptive Immune Response to Biomaterials and Tissue Repair  (13)    Antibody Responses Predict Antigen Exposure  (17)    Cytokine Receptor Structure  (8)    Human Antibody Response  (18)    Human Circulating Antibody Repertoire  (11)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (11)    Synthetic Immunology: Hacking Immune Cells  (15) Immunotherapy  (133)    CAR-T  (14)    combination immunotherapies.  (14)    Efficacy of Anti-Tumor T Cells  (13)    Engineering Better T Cells  (8)    Immune Engineering  (17)    Immune Modulatory  (15)    Integrin-targeted Combination Immunotherapy  (6)    Modulating Macrophages in Cancer Immunotherapy  (16)    NK Cell-Based Cancer Immunotherapy  (19)    Synergistic Innate and Adaptive Immunotherapy  (14) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (162)    Antibiotic resistance  (7)    Viral diseases  (37)       Myocarditis  (1) Infectious Disease Immunodiagnostics  (58)    Virology – Vector-borne DIsease  (17) Inflammasome  (29)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (3) Innovation in Immunology Diagnostics  (111)    Universal Immune Cell Therapies (uICT)  (11) Innovations  (186)    R&D Expenditure  (8) Innovations in Neurophysiology & Neuropsychology  (145)    Age and Life Expectancy  (3)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (6)    hNPCs  (1)    Nervous System Function  (2)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (83)    Disputes and Settlements  (9)    IP Valuation Models – Pricing Intangible Assets  (7)    Patent Law in Biotech  (12) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (119) International Global Work in Pharmaceutical  (190) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (315)    Albany Medical Center Prize in Medicine and Biomedical Research  (2)    Annual Breakthrough Prize  (4)    Annual Lewis S. Rosenstiel Award  (2)    Awards in Cardiology and Cardiovascular Medicine  (6)    CEOs of Biotech Companies  (3)    Gerald D Aurbach Award for Outstanding Translational Research  (2)    Interviews with Key Opinion Leaders (KOLs)  (10)    James Prize in Science and Technology Integration  (2)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (2)    Lemelson-MIT Prize  (2)    Life Sciences Breakthrough Prize  (5)    Mosteller Statistician of the Year Award  (2)    Mourning the Loss of a Scientific Leader  (3)    National Academy of Sciences AWARDS  (4)    Nobel Prize Winners  (29)    Noble Prize (Not Nobel Prize)  (2)    Paul Marks Prize for Cancer Research  (2)    Russ Prize recognizes bioengineering achievements worldwide  (2)    The Dan David Prize  (6)    Warren Alpert Foundation Prize Recipients  (4)    Wolf Prize  (2)    Wolf Prize in Medicine  (2)    women in science  (5) Investment in Technological Breakthrough  (60) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (14) IP Development by LPBI Group Team & Other Organizations  (8) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (14) Leadership, Power, Social Interlocking Connections  (13) Lipid metabolism  (109)    Fatty acids  (38)    Lipids  (38)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (11) Liposome  (4) Liver & Digestive Diseases Research  (122) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (143)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (9)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (27)    PhD  (1)    RN  (1) LPBI Management  (23) Massachusetts Academy of Sciences (MAS)    (2) Materials Science & Engineering  (37)    Organic BioElectronics  (2) Math  (13)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (193) Medical Devices R&D Investment  (242)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (14)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (59) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (164)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (3)    Echocardiography  (3)    MRI  (18)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (6)    Ultra Sound  (10) Melatonin & Circadian Regulation  (9) memory loss  (1) Metabolism  (239)    Biochemical pathways  (144)       Enzymes and isoenzymes  (73)          Dehydrogenase  (16)          Kinase  (28)          Phosphatase  (9)          Phosphorylase  (22)          tyrosine decarboxylases  (3)    Inosine nucleotides  (9)    Leloir pathway  (6)    microbiome  (7)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (321) Methods  (37) Mg++  (10) Microbiologial genetics  (36) Microbiology  (68)    Virology  (14) Micronutrients  (16) Microvesicle  (7) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (5) Molecular Genetics & Pharmaceutical  (377)    Organoids  (3) Monoclonal antibody therapy  (14) Mutant Gene Expression  (42) Myocardial adenine nucleotide metabolism  (6) Myocardial Ischemia  (26) Myocardial Metabolism  (36) Na-K transport  (40) Na-K-ATPase  (27) Nanotechnology for Drug Delivery  (99) Nephrology  (46) Nephrology & Regenerative medicine  (9) Neurodegenerative Diseases  (89)    hNPCs  (3)    MS  (5) Neurohumoral Transmission  (68)    Ca2+ triggered activation  (21)    Calmodulin  (13)    Parkinson’s disease dyskinesia levodopa  (3)    PKC  (13)    Synaptic vesicle  (20) Neurological Diseases  (121) Neuroscience  (126) Next Generation Sequencing (NGS)  (27)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (136) Nuclear Medicine  (11) Nutrigenomics  (68) Nutrition  (195)    Nutritional Supplements: Atherogenesis, lipid metabolism  (50) Nutrition and Phytochemistry  (62)    Minerals in Medicine  (4)    Plant extract  (22) Nutrition Disorders  (31) Nutritional Supplements: Atherogenesis  (31) Obesity  (19) Oligonucleotide Therapeutics & Delivery  (7) Oncolytic virus & OncoViro-Therapy  (22)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (24) Parasitology  (5)    Malaria  (4)    Tropical diseases  (1) Patents  (34) Patient Experience  (66)    Art therapy  (1)    Hospital reputation  (7)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (28)    Reputation of Interventionist  (4)    Support Staff  (13)    Supportive therapies  (6)       laughfter  (1)    Surgical Procedure  (9) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (2) Personal Health Applications: Tech Innovations serves HealhCare  (43) Personalized and Precision Medicine & Genomic Research  (736)    Longevity  (3)    New Drug Approval  (5)    Patient-centered Medicine  (39)       cell-based therapy  (9)       stem cell biology and patient-specific  (7)    Personalized Medicine Coalition  (10)    Precision Cancer Medicine  (31) Phagophore  (2) Pharmaceutical Analytics  (261)    Pharmacologic toxicities  (62) Pharmaceutical Discovery  (109)    Rapid automation of plasma protein pools  (17) Pharmaceutical Drug Discovery  (200)    Drug Development Process  (55)       Drug Discovery Chemistry  (29)    drug repurposing  (10) Pharmaceutical Industry Competitive Intelligence  (343)    Pharmacovigilance  (7)    Value-based Drug Pricing  (8) Pharmaceutical R&D Informatics  (44) Pharmaceutical R&D Investment  (299) Pharmacodynamics and Pharmacokinetics  (24) Pharmacogenomics  (159) Photography Collection  (1) Physics  (12) Placenta  (7) Population genetics  (27) Population Health Management  (204)    Evolution of Biology Through Culture  (14)    U.S. Employment-to-Population Ratio  (8) Population Health Management, Genetics & Pharmaceutical  (643)    COVID-19  (157)       Biomarkers: Inflammation  (37)       Cancer Researchers Fighting COVID-19  (14)       COVID-19 effects on Human Heart  (15)       COVID-19: Pandemic Surgery Guidance  (19)       Economic Impact of Coronavirus Pandemic  (41)       number of asymptomatic infections  (27)       Treatment Protocols for COVID-19  (62)    SARS-CoV-2  (141)       Coronavirus Gene Expression  (66)          SARS-CoV-2 circulating variants   (14)          SARS-CoV-2 Viral Variants  (19)       Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis  (2)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (30)       Mechanisms of infection by SARS-CoV-2  (21)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (35)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (19)       Seasonality & Environmental Factors in Resurgence  (26)       Serology tests for coronavirus antibodies  (44)       T-cell response to SARS-CoV-2 infection  (14)       Vaccinology  (51)          Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines  (5)       Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins  (8)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (92) Population Health Management, Nutrition and Phytochemistry  (162) Preimplantation Genetic Diagnosis and Reproductive Genomics  (13) Protein-energy malnutrition  (12) Proteomics  (367)    Amino acids  (54)    Proteins  (138) Pulmonary diseases  (16)    Lung and pulmonology  (15) Pulmonary pathology  (8) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (50) Regenerative Biology and Medicine  (92) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (265) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (113) Reproductive Biology & Bio Instrumentation  (78) RNA Biology  (81)    RNA interference (RNAi) therapeutic  (4) RNA Biology, Cancer and Therapeutics  (64) RVAD  (1) SBIR, SBA, NIH, NSF  (3) Schizophrenia  (16) Scientific & Biotech Conferences: Press Coverage  (182) Scientific Publishing  (609)    Curation  (585)       Curation methodology  (40)       De novo synthesis  (16)       Dialectic  (17)       Discovery process  (72)       Evolutionary cognition  (52)       Experimental validation  (91)       Explanatory  (91)       Historical relevance  (71)       Technology Advance Assessment of  (69)       Theoretic convergence  (27)    Open Access Journals  (37) Scientist: Career considerations  (197)    Big Data & Analytics  (17)    Data Science  (13)    Women in Life Sciences  (12) Scoop.it  (19) Sensors & Analytics  (18) Sepsis  (2) Severe Autism  (3) Signaling  (102)    Phosphorylation  (43)    S-nitrosylation  (13)    Ubiquitinylation  (34) Signaling & Cell Circuits  (130) single cell sequencing  (3) Small Molecules in Development of Therapeutic Drugs  (71) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (137) Stem Cells for Regenerative Medicine  (177)    Cardiac muscle regeneration  (19)    Competition in regenerative stem cell science  (18)    Human neural progenitor cells  (8)    Skeletal muscle regeneration  (9) STORM  (2) Stress Disorders  (19) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (161)    Inflammatory Pathophysiology  (9) Technology Transfer: Biotech and Pharmaceutical  (354) therapeutics  (3) Tissue Engineering and Regenerative Medicine  (22) Tissue Microenvironment  (5) Transarterial Chemoembolization  (2) Transcriptomics  (47) Transformative Technologies in Healthcare  (23) Translational Science  (230)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (29)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (6)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (92) Trends in Global Economy  (6) Uncategorized  (1,019) Unfolded Protein Response (UPR)  (6) US and Global Economy: Trends and Findings  (9) Venture Capital  (47)    Income Geographic Distribution  (3)    Institutional Capital Raised by Female Founders  (6) virology  (10) Vision  (7) Voices of Patients and Healthcare Providers  (22) Water Transporters  (8) Wearable Tech + Digital Health  (5) Anemia  (22) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (13) Myelofibrosis  (10)

• Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

• • 2012pharmaceutical
  • sjwilliamspa